Medco Commits $20 Mil. To Part D Development, Implementation Costs
This article was originally published in The Pink Sheet Daily
Executive Summary
Capital investment will be used to develop the infrastructure required to participate in the Medicare prescription drug program, including software programs and communication materials.
You may also be interested in...
Medco Creates Largest U.S. Specialty Pharmacy Through Accredo Acquisition
The companies' combined specialty drug sales were about $4.3 bil. in 2004. The acquisition puts Medco in a position to take a large share of Medicare Part B drug business in addition to its stake in the Part D outpatient drug benefit.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.